Evaluate Bone Changes in Patients With PsA

Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months

Abatacept 125 MG/ML

University Clinic Erlangen, Medical Department 3, Rheumatology & Immunology

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB

Change in bone erosion volume measured by Hr-PQ CT of the involved hand between baseline and 24 weeks follow-up

Change in bone erosion on CT between baseline and 24 wks

Change in osteophytes CT between baseline and 24 wks

Change in MRI Tenosynovitis score between baseline compared to month 3 and 6

Change in PSAMRIS MRI score between baseline compared to month 3 and 6

Change in MRI bone erosions between baseline compared to month 3 and month 6

Change in MRI synovitis between baseline compared to month 3 and month 6

Change of DAS28 between baseline compared to month 3 and month 6

Change of DAPSA between baseline compared to month 3 and month 6

Change of MDA between baseline compared to month 3 and month 6

Change of HAQ-DI between baseline compared to month 3 and month 6

Change of SPARCC between baseline compared to month 3 and month 6

Change of PSAID between baseline compared to month 3 and month 6

Change of PASI between baseline compared to month 3 and month 6

Change of SF36 between screening, month 3 and month 6

University of Erlangen-Nürnberg Medical School

The study is a single arm interventional study with a treatment phase of 6 months.

Obesity

Psoriatic Arthritis

Metabolic Syndrome

Psoriasis

Cardiovascular Disease

Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.

Very Low Energy Diet (VLED)

Department of Rheumatology at the Hospital of Alingsås

Department of Rheumatology at the Hospital of Borås

Department of Obesity and Internal Medicine at Sahlgrenska University Hospital

Department of Rheumatology at Sahlgrenska University Hospital

Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis

5 of 7 of the following criteria: Tender joint count ≤ 1 Swollen joint count ≤ 1 PASI ≤ 1or BSA ≤ 3 Patient pain VAS ≤ 15 Patient global activity VAS ≤ 20 HAQ ≤ 0.5 Tender entheseal points ≤ 1 BSA: body surface area; HAQ: Health Assessment Questionnaire; PASI

Vastra Gotaland Region

Intravitreal injections of 440mcg sirolimus (low-dose monthly group)

Intravitreal injections of 880mcg sirolimus (high-dose every other month group)

Uveitis

Intermediate Uveitis

Posterior Uveitis

Panuveitis

Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.

Intravitreal injection 440mcg

Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.

Intravitreal injection of sirolimus 880mcg

Stanford University

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis

Incidence, frequencey, and severity of adverse events reported during the first 6 months of the study period.

Improvement or worsening of macular edema compared to baseline. Development of macular edema in patients with otherwise normal macualr thickness at baseline

Proportion of subjects with active uveitis who achieve complete or partial response to sirolimus at month 6 while discontinuing their steroid therapy.
Proportion of subjects with inactive uveitis who maintain quiscent study eyes at month 6 while discontinuing their steroid therapy.

Quan Dong Nguyen

Professor

Santen Inc.

Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.

Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.

Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.

Intravitreal Injection

Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
Sirolimus (rapamycin): Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.

Subconjunctival Injection

Total

Sex: Female, Male

Race/Ethnicity, Customized

Vitreous Haze is calculated using a 9 step photographic haze in uveitis patients using fundus photograph

Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH)

Change From Baseline VA by ETDRS

Overall Study

Quan Dong Nguyen, MD, MSc

Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.

Sirolimus (rapamycin)

Wilmer Eye Institute at Johns Hopkins University

Sirolimus as Therapeutic Approach to Uveitis

A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis

uveitis/obesidad

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

Sirolimus as Therapeutic Approach to Uveitis

La base de datos de hierbas medicinales más completa respaldada por la ciencia